Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > KOL

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 05, 2023 2:43pm

108 Views

Post# 35480930

RE:RE:RE:RE:KOL

The surrogate endpoints of ORR and PFS have been defined as biomarkers intended to substitute for a clinical endpoint.

So ONCY has already defined the biomarkers and have reached them in the Phase 2 Bracelet-1 study. A Phase 3 will receive an Accelerated Approval based on the PFS surrogate endpoint which Big Pharma would be responsible in achieving, followed by OS.

<< Previous

Bullboard Posts

Next >>

Catching up with one of the busiest junior gold developers